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Abstract 
Background: 
Allopurinol reduces oxidative stress and interacts with purinergic signalling systems important 
in bone metabolism and muscle function. We assessed whether allopurinol use was associated 
with a reduced incidence of hip fracture in older people. 
 
Methods: 
Analysis of prospective, routinely-collected health and social care data on patients undergoing 
health and social work assessment in a single geographical area over a 12 year period. Exposure 
to allopurinol was derived from linked community prescribing data, hospitalisation for hip 
fracture and comorbid disease was derived from linked hospitalisation data. Fine and Gray 
modelling was used to model time to hip fracture accounting for the competing risk of death, 
incorporating previous use of allopurinol, cumulative exposure to allopurinol as a time 
dependent variable, and covariate adjustments. 
 
Results: 
17308 patients were alive at the time of first social work assessment without previous hip 
fracture; the mean age was 73 years. 10171 (59%) were female, and 1155 (8%) had at least one 
exposure to allopurinol. 618 (3.6%) sustained a hip fracture, and 4226 (24%) died during a 
mean follow up of 7.2 years. In fully-adjusted analyses, each year of allopurinol exposure 
conferred a hazard ratio of 1.01 (95% CI 0.99, 1.02; p=0.37) for hip fracture and 1.00 (0.99, 
1.01; p=0.47) for death. Previous use of allopurinol conferred a hazard ratio of 0.76 (0.45, 1.26; 
p=0.28) for hip fracture and 1.13 (0.99, 1.29; p=0.07) for death. 
 
Conclusion:  
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Greater cumulative use of allopurinol was not associated with a reduced risk of hip fracture or 
death in this cohort. 
 
 
Keywords: Gout, fracture, older, allopurinol, risk factor 
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Introduction 
Falls and fragility fractures remain a major global healthcare issue for older people. Although 
a range of effective therapies for osteoporosis and falls have been available for several years, 
admissions to hospital for osteoporosis-related fractures remain high, with major healthcare 
costs [1]. Effective prevention of fragility fractures requires that risk factors for both falling 
(e.g. impaired balance, sarcopenia) and impaired bone structure (osteoporosis/osteopenia) are 
addressed [2]; few interventions currently available address both of these aspects of fracture 
prevention. 
 
Recent advances in bone and muscle biology have revealed two biological pathways of 
relevance to the current investigation. Firstly, purinergic signalling has been shown to play an 
important role in bone biology [3], and also has a potential role in muscle biology [4]. Multiple 
types of puringeric receptor are found on both myocytes [5], osteoblasts and osteoclasts; 
signalling via the actions of ATP on purinergic receptors can enhance osteoclast function and 
inhibit matrix mineralisation by osteoblasts [4]. Other agents with purinergic effects (e.g. 
clopidogrel) have been shown to have important biological effects on osteoblast function, again 
reducing mineralisation [6]. It is therefore possible that other agents active at selected 
purinergic receptor subtypes might have the ability to inhibit the deleterious effects of ATP on 
bone mineralisation. Secondly, oxidative stress has been shown to have a key role in both 
impaired muscle function (a factor in falls in older people) [7] via reduction of mitochondrial 
efficiency, and in bone biology. Reactive oxygen species such as hydrogen peroxide and the 
superoxide anion inhibit both osteoblast differentiation and expression of genes required for 
new bone formation. [8, 8a-8c]. Given the deleterious effects of oxidative stress on both muscle 
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and bone biology, agents that inhibit the formation of reactive oxygen species might have 
benefit in improving muscle function and bone formation, hence reducing the risk of fracture. 
 
Allopurinol is a prodrug commonly used to treat gout, via its effects on inhibition of xanthine 
oxidase. However, xanthine oxidase is also a powerful generator of reactive oxygen species; 
allopurinol treatment has been shown to dramatically reduce oxidative stress in other organ 
systems, particularly the cardiovascular system [9]. In addition, allopurinol, as a purine analog, 
may have direct actions at purinergic receptors, and by inhibiting breakdown of purinergic 
nucleotides (e.g. ADP) by xanthine oxidase, it may also indirectly modulate the impact of ADP 
on purinergic signalling systems. However, any relationship between allopurinol use and 
fracture is likely to be complex; recent observational data suggest that elevated circulating urate 
levels are associated with higher bone mineral density and lower fracture risk [10-14], possibly 
due to antioxidant effects of urate itself. Hence analyses of the effect of allopurinol on fracture 
risk need to try and separate the effect of gout (a consequence of hyperuricemia) from gout 
treatment (allopurinol). 
 
We have previously shown that allopurinol use is associated with greater improvements in 
functional status in older patients undergoing inpatient rehabilitation [15]. The aim of this 
analysis was to explore whether, given the biological actions of allopurinol outlined above, 
allopurinol use is associated with lower rates of fragility fractures and injurious falls in a group 
of older patients referred to social services. 
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Methods 
Study population 
We studied a cohort of older patients referred to social services over a 12 year period (January 
2000 to December 2011) in Dundee, Scotland. Details of the linked datasets used in this 
analysis have been published previously [16,17]. The Dundee social work database contains 
routinely collected data on clients including details of care packages provided or commissioned 
by social work. We have linked data on those clients aged 65 and over with data held by the 
University of Dundee Health Informatics Centre (HIC) on a range of other routinely collected 
healthcare data. Information on community prescribing, biochemistry and haematology results, 
plus hospitalization data and diagnoses (Scottish Morbidity Register 01) coded using ICD-10 
codes were accessible. Data from the Scottish Government Records Office, which records all 
deaths registered within Scotland, was held by HIC and was used as a source for date of death. 
For this analysis, data from the first assessment by Dundee Social Work were used. Analyses 
were confined to those aged 65 and over; those with a hip fracture sustained prior to the date 
of discharge from rehabilitation were excluded because their very high rate of death, further 
fracture and dependency could lead to an altered relationship between prescribing patterns and 
outcomes. Use of this dataset allowed us to study a group of older people at risk of dependency 
(hence their referral for social work assessment) and therefore at higher risk of adverse events; 
the presence of data on provision of care packages allowed use of this as a proxy measure of 
functional impairment – a powerful indicator of future adverse events including falls, fractures 
and death – to be included in the analyses. 
 
Allopurinol exposure 
Allopurinol use was obtained from prescription records of patients held within HIC data for 
community based prescriptions. The number of days of allopurinol prescription was used as a 
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measurement of exposure. Two indices of exposure were calculated: a) the cumulative number 
of years of allopurinol dispensed after discharge from rehabilitation, b) a flag denoting those 
who had been dispensed any prescription for allopurinol prior to the date of social work 
assessment.  Allopurinol is prescribed for gout, which is itself associated with cardiovascular 
disease [18] and hence an increased rate of death and disability. Use of a ‘previously exposed’ 
variable thus allowed the effect of confounding by indication to be separated from the effect of 
cumulative allopurinol exposure, and separation of pre- and post-admission exposure allowed 
time-dependent analysis to be performed from a defined start point whilst still taking into 
account previous exposure. 
 
Definition of outcome events 
Data on hospitalisations for hip fractures were obtained for each patient using records held 
within HIC data. Relevant ICD-10 codes were identified and used to flag the date of events. 
ICD-10 codes for hip fracture were S72.0, S72.1, S72.2, S72.8 and S72.9. Primary and 
secondary diagnosis codes were included. The number of days from social services assessment 
to the date of first admission for which a hip fracture discharge code was present was then 
calculated for each patient who suffered such an event. Those who suffered a fracture prior to 
rehabilitation were not included in the analysis. Time to first event, time to death or time until 
the censoring date of 16/05/2013 (if still alive with no events) was calculated. 
 
Covariates 
To allow adjustment for potential confounders, a series of covariates were identified. These 
were chosen by assessing their possible effects on hip fracture risk, co morbidity and possible 
interaction with Allopurinol therapy.  Details of age and sex were acquired from population 
records contained within HIC data. Information regarding previous hospital admission with a 
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diagnosis of myocardial infarction, stroke, heart failure or chronic obstructive pulmonary 
disease were obtained from ICD-10 codes also contained within HIC database data. Diagnosis 
of diabetes mellitus was obtained from the SCI-DC dataset (19), which records all diagnoses 
of diabetes for Scotland. The most recent creatinine measurement prior to the date of social 
work assessment was obtained from routinely collected biochemistry records held in HIC. 
Bisphosphonate medication and calcium and vitamin D use at the time of social work 
assessment were included as covariates. HIC data records dispensed community (not in-
hospital) prescriptions for all participants; use of medications was flagged as positive if at least 
one dispensed prescription was recorded within three months of the index date. We extracted 
data on whether a package of social care (defined as any frequency of home visits for personal 
care paid for by the Social Work service) was in place within a month of social work 
assessment; this indicator was used as a proxy measure of functional impairment given that 
direct measures of impairment in physical or social function are not held as part of routinely 
collected electronic data in the study area. 
 
Data Analysis 
All data analyses were performed using STATA v14 (STATA Corp, New York, USA). A p 
value of <0.05 was taken as significant for all analyses. We used Fine and Gray competing 
risks models to estimate the effect of cumulative allopurinol exposure (as a time-dependant 
variable) on time to first hip fracture, with death as a competing risk. We used time-dependent 
Cox-regression analysis to model the effect of allopurinol on time to death. Unadjusted 
analyses were performed, along with analyses including the following covariates:  age, sex, 
creatinine, albumin, haemoglobin, diagnosis of diabetes mellitus, previous admission with 
ischaemic heart disease, stroke, chronic heart failure, COPD, bisphosphonate prescription, 
vitamin D and calcium prescription, any exposure to allopurinol prior to the index date, and 
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provision of a package of social care. We performed sensitivity analysis using multiple 
imputation to account for missing baseline covariates, and a further sensitivity analysis 
including only those patients with exposure to allopurinol at any time; this was done as an 
alternative to propensity score matching as baseline predictors were unable to accurately 
calculate propensity for allopurinol use. For each analysis, cumulative exposure to allopurinol 
post-discharge was included as the time-dependent covariate, taking into account that doses 
varied from 100mg per day to 300mg per day. Cumulative exposure was expressed as 
equivalent years of 300mg exposure (thus a year of exposure to 100mg per day of allopurinol 
would count as one third of a year exposure). We also analysed time to first hip fracture 
separately for males and females, given the very different event rates seen in these populations. 
 
Results 
17308 patients who were alive without a prior hip fracture at the time of social work assessment 
were included in the study cohort. The mean follow up time was 7.2 (SD 4.4) years. Baseline 
details of the cohort are given in Table 1. 1401 (8.1%) of patients had missing covariates 
(haemoglobin or creatinine) and were thus not included in the Cox regression analyses, leaving 
a total of 15907 patients included in the final analysis. Of these, 565 were admitted to hospital 
with hip fracture. 
 
Table 2 shows the results of the regression analyses for each outcome. We also performed 
subgroup analyses for males and females separately; the hazard ratio for hip fracture per year 
of allopurinol exposure was 1.03 (95% CI 1.01 to 1.04; p<0.001) for females, and 1.01 (95% 
CI 0.99 to 1.03; p=0.28) for males, but with no significant interaction on formal interaction 
testing. 
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Sensitivity analyses showed little difference; when including only those patients with any 
exposure at any time to allopurinol, the risk of hip fracture per year of exposure post-assessment 
was 1.00 (95%CI 0.99 to 1.02; p=0.62) and for death was 1.00 (95%CI 0.99 to 1.00; p=0.18). 
No difference in effect sizes was noted using multiple imputation to account for missing 
haemoglobin and creatinine data. 
 
Discussion 
This analysis is the first to our knowledge to examine the relationship between allopurinol use 
and hospitalisation for hip fracture. A key feature of the analysis was our ability to adjust for a 
range of important potential modifiers of risk, including functional status, as well as the use of 
routinely collected outcome and community prescribing data. Despite these adjustments, 
neither cumulative nor previous exposure to allopurinol was associated with differences in rates 
of death or hip fracture. 
 
Previous studies have found a variable relationship between serum urate and osteoporosis and 
fractures. Several studies found that higher serum urate (which is a major risk factor for gout) 
is associated with higher bone mineral density and a lower risk of fracture [10-14]; one recent 
study showed no relationship between serum urate and fracture rates in older people [21], 
another recent study found that higher urate was associated with higher fracture rates in men 
[22]. Gout, ascertained by any use of allopurinol in a large Danish registry, was associated with 
higher fracture rates in men but not women [23]. Although urate has been postulated to have 
protective effects on bone loss via antioxidant effects, such effects might be lost or 
overwhelmed by the inflammatory stimulus of gout; inflammation is thought to drive both 
osteoporosis and sarcopenia, which could explain the divergent associations seen between 
fracture risk and gout and asymptomatic hyperuricaemia and fracture risk. In addition, uric acid 
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has been shown to suppress 1-alpha hydroxylase activity, accounting for associations found 
between high urate and high PTH, and between high urate and lower serum 1,25 
hydroxyvitamin D [24]; these changes would again be expected to have deleterious effects on 
bone health.  
 
Allopurinol use has been associated with improved functional outcomes after rehabilitation in 
older people [15], and recent in vitro work has shown that allopurinol and its active metabolite, 
oxypurinol, both enhance bone formation by osteoblasts in culture [25]. It is therefore possible 
that whilst allopurinol provides some potential beneficial effects on bone metabolism and 
muscle function, its actions in reducing urate levels (which themselves have antioxidant 
activity) negates these by removing the beneficial effects of urate on bone health. Thus the two 
effects would cancel out, showing no net effect on hip fracture rates as we observed.  Other 
explanations are possible, particularly due to confounding. For instance the presence of heart 
failure is a powerful risk factor for both death and fractures. Treatment of heart failure entails 
use of diuretics – which may increase the risk of symptomatic gout and hence allopurinol 
prescription. Thus allopurinol use would be greater in the group of patients at higher risk of 
death or fracture – hence masking any potential beneficial effect of allopurinol. 
 
Our study had a number of strengths. Use of routinely collected data greatly improves the 
generalizability of our results; such data includes patients with cognitive impairment and frailty 
that would usually preclude entry to clinical trials or cohort research studies. Using social work 
data allows the presence of a package of social care (as a proxy measure of physical function) 
to be used as a covariate – critical in studies of falls and fracture risk, yet often not obtainable 
from routinely collected healthcare data. We were also able to use data on dispensed 
prescriptions, which gives a robust estimate of cumulative drug exposure, and allows for 
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adjustment for other prescriptions known to influence fracture risk. The high death rate in this 
cohort poses the issue of competing risks, but the use of Fine and Gray modelling takes this 
issue into account. Finally, the use of multiple indices of allopurinol exposure, including a 
factor to characterise ever-exposure to allopurinol, allows for at least some minimisation of 
confounding by indication. 
 
A number of weaknesses deserve comment. Only a small proportion of patients were exposed 
to allopurinol, limiting the power of the study. We limited our analysis to hip fracture, as this 
invariably leads to hospitalisation. Other fractures (e.g. of wrist or pelvis) do not always lead 
to hospitalisation, and thus the use of hospital data such as in this study cannot ascertain all 
occurrences of such fractures. Routinely collected data may suffer from incomplete 
ascertainment and inaccurate coding, which are further potential sources of bias if they affect 
the exposure groups differentially. We did not have access to a direct measure of physical or 
psychosocial function, as such measures are not collected electronically on all older people in 
the study area; the presence of a package of social care provides an indirect measure of 
functional impairment, but the need for such a package is moderated by other variables, such 
as the environment the patients lives in, and the amount of informal care (e.g. from spouse or 
offspring) available to the patient. 
 
Despite access to a range of covariates associated with falls and fracture risk, there are a number 
of variables that we were unable to adjust for. We do not have access to data on bone mineral 
density, body mass index, cognitive function or balance – all important variables in ascertaining 
fracture risk. Higher body mass index in particular is associated with lower risk of fracture, but 
is also linked to higher urate levels and hence indications for use of allopurinol. Functional 
status was ascertained at a single point in time, and we are therefore unable to account for 
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changes in functional status and falls risk over time; the measure we used was a proxy for 
functional impairment, and direct measurements of lower limb function and balance would 
provide more accurate data on fall and fracture risk. 
 
Lastly, and most importantly, any observational analysis cannot completely account for 
confounding by indication. This is a particular problem for studies of allopurinol – the drug is 
given only for gout, and gout is closely associated with elevated urate levels. Elevated urate is 
in turn a powerful marker of vascular disease and death [26], and vascular disease is in turn 
associated both with osteoporosis and with functional impairment [27]. In our analysis, 
allopurinol use was much more common in those with a previous hospital admission for 
myocardial infarction or heart failure. This may be driven by diuretic use in these conditions, 
which is known to precipitate gout and would therefore be expected to lead to greater use of 
allopurinol. Only randomised controlled trials will be able to dissect out whether allopurinol 
use might be causally linked to differences in death rates and fractures, but in the meantime, 
future observational work using larger databases with more events would help to ascertain 
whether there is a statistically and clinically significant association between allopurinol use, 
falls and fragility fractures.  
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Table 1. Baseline details 
 Ever exposed to  
allopurinol  
(n=1115) 
Not exposed to  
allopurinol 
(n=16153) 
p 
Mean age (years) (SD) 73.2 (8.4) 73.4 (9.0) 0.44 
Female sex (%) 487 (43.7) 9684 (60.0) <0.001 
Previous admission with myocardial 
infarction (%) 
175 (15.7) 1269 (7.9) <0.001 
Previous admission with stroke (%)  64 (5.7)  973 (6.0) 0.50 
Previous admission for heart failure (%) 175 (15.7) 782 (4.8) <0.001 
Previous admission for chronic obstructive 
pulmonary disease (%) 
85 (7.6) 1046 (6.5) 0.24 
Diabetes mellitus (%) 268 (24.0) 1972 (12.2) <0.001 
Baseline creatinine (umol/L) (SD) 131 (105) 94 (54) <0.001 
Baseline haemoglobin (g/dL) (SD) 12.5 (2.1) 12.8 (1.9) <0.001 
Baseline use of calcium+vitamin D (%) 69 (6.2) 8998 (5.6) 0.56 
Baseline use of bisphosphonates (%) 40 (3.6) 698 (4.3) 0.16 
Admission for hip fracture (%) 25 (2.2)  593 (3.7) 0.008 
Died during follow up (%) 362 (32.5) 3864 (23.9) <0.001 
Receiving care package at baseline (%) 68 (6.1) 1119 (6.9) 0.18 
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Table 2. Time-dependent Cox regression analysis – time to hip fracture and death 
 Hip fracture Death 
Factor HR (95% CI) p HR (95% CI) p 
Unadjusted analysis 
Allopurinol exposure (per year) 1.01 (0.99-1.02) 0.34 1.00 (1.00-1.01) 0.56 
Adjusted analysis* 
Allopurinol exposure (per year) 1.01 (0.99-1.02) 0.37 1.00 (0.99-1.01) 0.47 
Age 1.06 (1.05-1.07) <0.001 1.02 (1.02-1.03) <0.001 
Sex (female) 1.95 (1.60-2.37) <0.001 0.60 (0.56-0.64) <0.001 
Myocardial infarction 1.01 (0.74-1.37) 0.96 1.10 (1.00-1.22) 0.05 
Stroke 1.40 (1.05-1.88) 0.02 1.32 (1.17-1.48) <0.001 
Heart failure 1.09 (0.77-1.53) 0.63 1.81 (1.63-2.00) <0.001 
Chronic obstructive pulmonary 
disease 
1.18 (0.84-1.65) 0.34 2.05 (1.87-2.26) <0.001 
Diabetes mellitus 0.90 (0.68-1.18) 0.43 1.07 (0.98-1.17) 0.11 
Creatinine (per umol/L) 1.001 (1.000-1.002) 0.16 1.001 (1.001-1.001) <0.001 
Haemoglobin (per g/dL) 0.99 (0.94-1.04) 0.70 0.80 (0.79-0.81) <0.001 
Previous allopurinol use 0.76 (0.45-1.26) 0.28 1.13 (0.99-1.29) 0.07 
Bisphosphonate use 1.75 (1.19-2.59) 0.004 1.02 (0.85-1.24) 0.81 
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Calcium/vitamin D use 1.43 (0.97-2.11) 0.07 0.83 (0.70-0.98) 0.03 
Package of care 2.59 (1.97-3.41) <0.001 0.30 (0.24-0.37) <0.001 
*Forced entry multivariable model; each variable adjusted for others in the model. 
 
 
 
 
